Glucocorticoid Signaling: An Update from a Genomic Perspective

Annual Review of Physiology

Volumn 78, Issue , 2016, Pages 155-180

  Sacta, Maria A ^a,b   Chinenov, Yurii ^a   Rogatsky, Inez ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Genomic approaches; Glucocorticoid receptor; Next generation sequencing; Transcriptional regulation

Indexed keywords

GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR;

ANIMAL; GENETICS; GENOME; GENOMICS; HUMAN; METABOLISM; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; GENOME; GENOMICS; GLUCOCORTICOIDS; HUMANS; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84958642615     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021115-105323     Document Type: Review

References (163)

1. Angelier F, Wingfield JC. 2013. Importance of the glucocorticoid stress response in a changing world: theory, hypotheses and perspectives. Gen. Comp. Endocrinol. 190:118-28
2. Walker JJ, Spiga F, Waite E, Zhao Z, Kershaw Y, et al. 2012. The origin of glucocorticoid hormone oscillations. PLOS Biol. 10:e1001341
3. Landys MM, Ramenofsky M, Wingfield JC. 2006. Actions of glucocorticoids at a seasonal baseline as compared to stress-related levels in the regulation of periodic life processes. Gen. Comp. Endocrinol. 148:132-49
4. Oakley RH, Cidlowski JA. 2013. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J. Allergy Clin. Immunol. 132:1033-44
5. Romero LM, Dickens MJ, Cyr NE. 2009. The Reactive Scope Model-A new model integrating homeostasis, allostasis, and stress. Horm. Behav. 55:375-89
6. Crespi EJ, Williams TD, Jessop TS, Delehanty B. 2013. Life history and the ecology of stress: How do glucocorticoid hormones influence life-history variation in animals? Funct. Ecol. 27:93-106
7. Simons SS Jr. 2008. What goes on behind closed doors: physiological versus pharmacological steroid hormone actions. BioEssays 30:744-56
8. Vandevyver S, Dejager L, Libert C. 2012. On the trail of the glucocorticoid receptor: into the nucleus and back. Traffic 13:364-74
9. Vandevyver S, Dejager L, Libert C. 2014. Comprehensive overview of the structure and regulation of the glucocorticoid receptor. Endocr. Rev. 35:671-93
10. Gomez-Sanchez E, Gomez-Sanchez CE. 2014. The multifaceted mineralocorticoid receptor. Compr. Physiol. 4:965-94
11. Thornton JW. 2001. Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. PNAS 98:5671-76
12. Ortlund EA, Bridgham JT, Redinbo MR, Thornton JW. 2007. Crystal structure of an ancient protein: evolution by conformational epistasis. Science 317:1544-48
13. Strahle U, Klock G, Schutz G. 1987. A DNA sequence of 15 base pairs is sufficient to mediate both glucocorticoid and progesterone induction of gene expression. PNAS 84:7871-75
14. Surjit M, Ganti KP, Mukherji A, Ye T, Hua G, et al. 2011. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 145:224-41
15. Hudson WH, Youn C, Ortlund EA. 2013. The structural basis of direct glucocorticoid-mediated transrepression. Nat. Struct. Mol. Biol. 20:53-58
16. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB. 1991. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352:497-505
17. Hudson WH, Youn C, Ortlund EA. 2014. Crystal structure of the mineralocorticoid receptor DNA binding domain in complex with DNA. PLOS ONE 9:e107000
18. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, et al. 1990. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62:1189-204
19. DiamondMI, Miner JN, Yoshinaga SK, Yamamoto KR. 1990. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249:1266-72
20. Garza AM, Khan SH, Kumar R. 2010. Site-specific phosphorylation induces functionally active conformation in the intrinsically disordered N-terminal activation function (AF1) domain of the glucocorticoid receptor. Mol. Cell. Biol. 30:220-30
21. Arriza JL, Simerly RB, Swanson LW, Evans RM. 1988. The neuronal mineralocorticoid receptor as a mediator of glucocorticoid response. Neuron 1:887-900
22. Rupprecht R, Arriza JL, Spengler D, Reul JM, Evans RM, et al. 1993. Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol. Endocrinol. 7:597-603
23. Taves MD, Plumb AW, Sandkam BA, Ma C, Van Der Gugten JG, et al. 2015. Steroid profiling reveals widespread local regulation of glucocorticoid levels during mouse development. Endocrinology 156:511-22
24. Hunter RW, Bailey MA. 2015. Glucocorticoids and 11 β-hydroxysteroid dehydrogenases: mechanisms for hypertension. Curr. Opin. Pharmacol. 21:105-14
25. Leliavski A, Dumbell R, Ott V, Oster H. 2015. Adrenal clocks and the role of adrenal hormones in the regulation of circadian physiology. J. Biol. Rhythms 30:20-34
26. Lightman SL, Conway-Campbell BL. 2010. The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration.Nat. Rev. Neurosci. 11:710-18
27. Ishida A, Mutoh T, Ueyama T, Bando H, Masubuchi S, et al. 2005. Light activates the adrenal gland: timing of gene expression and glucocorticoid release. Cell Metab. 2:297-307
28. Chung S, Son GH, Kim K. 2011. Circadian rhythm of adrenal glucocorticoid: its regulation and clinical implications. Biochim. Biophys. Acta 1812:581-91
29. Son GH, Chung S, Choe HK, Kim HD, Baik SM, et al. 2008. Adrenal peripheral clock controls the autonomous circadian rhythm of glucocorticoid by causing rhythmic steroid production. PNAS 105:20970-75
30. Abe K, Kroning J, Greer MA, Critchlow V. 1979. Effects of destruction of the suprachiasmatic nuclei on the circadian rhythms in plasma corticosterone, body temperature, feeding and plasma thyrotropin. Neuroendocrinology 29:119-31
31. Walker JJ, Terry JR, Lightman SL. 2010. Origin of ultradian pulsatility in the hypothalamic-pituitaryadrenal axis. Proc. R. Soc. B 277:1627-33
32. Stavreva DA, Wiench M, John S, Conway-Campbell BL, McKenna MA, et al. 2009. Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat. Cell Biol. 11:1093-102
33. Conway-Campbell BL, George CL, Pooley JR, Knight DM, Norman MR, et al. 2011. The HSP90 molecular chaperone cycle regulates cyclical transcriptional dynamics of the glucocorticoid receptor and its coregulatory molecules CBP/p300 during ultradian ligand treatment. Mol. Endocrinol. 25:944-54
34. Conway-Campbell BL, Sarabdjitsingh RA, McKenna MA, Pooley JR, Kershaw YM, et al. 2010. Glucocorticoid ultradian rhythmicity directs cyclical gene pulsing of the clock gene period 1 in rat hippocampus. J. Neuroendocrinol. 22:1093-100
35. Stavreva DA, Coulon A, Baek S, Sung MH, John S, et al. 2015. Dynamics of chromatin accessibility and long-range interactions in response to glucocorticoid pulsing. Genome Res. 25:845-57
36. Henley DE, Russell GM, Douthwaite JA, Wood SA, Buchanan F, et al. 2009. Hypothalamic-pituitaryadrenal axis activation in obstructive sleep apnea: the effect of continuous positive airway pressure therapy. J. Clin. Endocrinol. Metab. 94:4234-42
37. Windle RJ, Wood SA, Kershaw YM, Lightman SL, Ingram CD, Harbuz MS. 2008. Increased corticosterone pulse frequency during adjuvant-induced arthritis and its relationship to alterations in stress responsiveness. J. Neuroendocrinol. 13:905-11
38. Henley DE, Lightman SL. 2014. Cardio-metabolic consequences of glucocorticoid replacement: relevance of ultradian signalling. Clin. Endocrinol. 80:621-28
39. Fardet L, Feve B. 2014. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs 74:1731-45
40. Robblee JP,Miura MT, Bain DL. 2012. Glucocorticoid receptor-promoter interactions: Energetic dissection suggests a framework for the specificity of steroid receptor-mediated gene regulation. Biochemistry 51:4463-72
41. Nagaich AK,Walker DA, Wolford R, Hager GL. 2004. Rapid periodic binding and displacement of the glucocorticoid receptor during chromatin remodeling. Mol. Cell 14:163-74
42. Stavreva DA, Muller WG, Hager GL, Smith CL, McNally JG. 2004. Rapid glucocorticoid receptor exchange at a promoter is coupled to transcription and regulated by chaperones and proteasomes. Mol. Cell. Biol. 24:2682-97
43. Ong KM, Blackford JA Jr, Kagan BL, Simons SS Jr, Chow CC. 2010. A theoretical framework for gene induction and experimental comparisons. PNAS 107:7107-12
44. Schiller BJ, Chodankar R, Watson LC, Stallcup MR, Yamamoto KR. 2014. Glucocorticoid receptor binds half sites as a monomer and regulates specific target genes. Genome Biol. 15:418
45. Starick SR, Ibn-Salem J, Jurk M, Hernandez C, Love MI, et al. 2015. ChIP-exo signal associated with DNA-binding motifs provides insight into the genomic binding of the glucocorticoid receptor and cooperating transcription factors. Genome Res. 25:825-35
46. Lim HW, Uhlenhaut NH, Rauch A, Weiner J, Hubner S, et al. 2015. Genomic redistribution of GR monomers and dimers mediates transcriptional response to exogenous glucocorticoid in vivo. Genome Res. 25:836-44
47. DigmanMA, Dalal R, Horwitz AF, Gratton E. 2008. Mapping the number of molecules and brightness in the laser scanning microscope. Biophys. J. 94:2320-32
48. PresmanDM, Ogara MF, StortzM, Alvarez LD, Pooley JR, et al. 2014. Live cell imaging unveils multiple domain requirements for in vivo dimerization of the glucocorticoid receptor. PLOS Biol. 12:e1001813
49. Gebhardt JC, Suter DM, Roy R, Zhao ZW, Chapman AR, et al. 2013. Single-molecule imaging of transcription factor binding to DNA in live mammalian cells. Nat. Methods 10:421-26
50. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR. 2009. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324:407-10
51. Watson LC, Kuchenbecker KM, Schiller BJ, Gross JD, Pufall MA, Yamamoto KR. 2013. The glucocorticoid receptor dimer interface allosterically transmits sequence-specific DNA signals. Nat. Struct. Mol. Biol. 20:876-83
52. Kassel O, Herrlich P. 2007. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol. Cell. Endocrinol. 275:13-29
53. Ratman D, Vanden BergheW, Dejager L, Libert C, Tavernier J, et al. 2013. How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol. Cell. Endocrinol. 380:41-54
54. Cooper CD, Newman JA, Gileadi O. 2014. Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition. Biochem. Soc. Trans. 42:130-38
55. VinsonC, Acharya A, Taparowsky EJ. 2006. Deciphering B-ZIP transcription factor interactions in vitro and in vivo. Biochim. Biophys. Acta 1759:4-12
56. Wan F, Lenardo MJ. 2009. Specification of DNA binding activity of NF-κB proteins. Cold Spring Harb. Perspect. Biol. 1:a000067
57. Lelli KM, Slattery M, Mann RS. 2012. Disentangling the many layers of eukaryotic transcriptional regulation. Annu. Rev. Genet. 46:43-68
58. Chinenov Y, Gupte R, Rogatsky I. 2013. Nuclear receptors in inflammation control: repression by GR and beyond. Mol. Cell. Endocrinol. 380:55-64
59. Engblom D, Kornfeld JW, Schwake L, Tronche F, Reimann A, et al. 2007. Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. Genes Dev. 21:1157-62
60. Guo L, Lichten LA, Ryu MS, Liuzzi JP, Wang F, Cousins RJ. 2010. STAT5-glucocorticoid receptor interaction and MTF-1 regulate the expression of ZnT2 (Slc30a2) in pancreatic acinar cells. PNAS 107:2818-23
61. Rogatsky I, Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, et al. 2003. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. PNAS 100:13845-50
62. Rogatsky I, Luecke HF, Leitman DC, Yamamoto KR. 2002. Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. PNAS 99:16701-6
63. Luecke HF, Yamamoto KR. 2005. The glucocorticoid receptor blocks P-TEFb recruitment by NFκB to effect promoter-specific transcriptional repression. Genes Dev. 19:1116-27
64. Gupte R, Muse GW, Chinenov Y, Adelman K, Rogatsky I. 2013. Glucocorticoid receptor represses proinflammatory genes at distinct steps of the transcription cycle. PNAS 110:14616-21
65. Langlais D, Couture C, Balsalobre A, Drouin J. 2012. The Stat3/GR interaction code: predictive value of direct/indirect DNA recruitment for transcription outcome. Mol. Cell 47:38-49
66. Berg OG, Winter RB, von Hippel PH. 1981. Diffusion-driven mechanisms of protein translocation on nucleic acids.1. Models and theory. Biochemistry 20:6929-48
67. Chen J, Zhang Z, Li L, Chen BC, Revyakin A, et al. 2014. Single-molecule dynamics of enhanceosome assembly in embryonic stem cells. Cell 156:1274-85
68. Polman JA, Hunter RG, Speksnijder N, van den Oever JM, Korobko OB, et al. 2012. Glucocorticoids modulate the mTOR pathway in the hippocampus: differential effects depending on stress history. Endocrinology 153:4317-27
69. Reddy TE, Pauli F, Sprouse RO, Neff NF, Newberry KM, et al. 2009. Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. Genome Res. 19:2163-71
70. Rao NA, McCalman MT, Moulos P, Francoijs KJ, Chatziioannou A, et al. 2011. Coactivation of GR and NFKB alters the repertoire of their binding sites and target genes. Genome Res. 21:1404-16
71. Park SG, Hannenhalli S, Choi SS. 2014. Conservation in first introns is positively associated with the number of exons within genes and the presence of regulatory epigenetic signals. BMC Genomics 15:526
72. John S, Sabo PJ,Thurman RE, SungMH, Biddie SC, et al. 2011. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet. 43:264-68
73. Tang Q, Chen Y, Meyer C, Geistlinger T, Lupien M, et al. 2011. A comprehensive view of nuclear receptor cancer cistromes. Cancer Res. 71:6940-47
74. Grontved L, John S, Baek S, Liu Y, Buckley JR, et al. 2013. C/EBP maintains chromatin accessibility in liver and facilitates glucocorticoid receptor recruitment to steroid response elements. EMBO J. 32:1568-83
75. Reddy TE, Gertz J, Crawford GE, Garabedian MJ,Myers RM. 2012. The hypersensitive glucocorticoid response specifically regulates Period 1 and expression of circadian genes. Mol. Cell. Biol. 32:3756-67
76. Biddie SC, John S, Sabo PJ,Thurman RE, Johnson TA, et al. 2011. Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. Mol. Cell 43:145-55
77. Uhlenhaut NH, Barish GD, Yu RT, Downes M, Karunasiri M, et al. 2013. Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol. Cell 49:158-71
78. Steger DJ, Grant GR, Schupp M, Tomaru T, Lefterova MI, et al. 2010. Propagation of adipogenic signals through an epigenomic transition state. Genes Dev. 24:1035-44
79. Rhee HS, Pugh BF. 2011. Comprehensive genome-wide protein-DNA interactions detected at singlenucleotide resolution. Cell 147:1408-19
80. Serandour AA, Brown GD, Cohen JD, Carroll JS. 2013. Development of an Illumina-based ChIPexonuclease method provides insight into FoxA1-DNA binding properties. Genome Biol. 14:R147
81. Simons SS Jr, Kumar R. 2013. Variable steroid receptor responses: Intrinsically disordered AF1 is the key. Mol. Cell. Endocrinol. 376:81-84
82. Stashi E, York B, O'Malley BW. 2014. Steroid receptor coactivators: servants and masters for control of systems metabolism. Trends Endocrinol. Metab. 25:337-47
83. Rollins DA, Coppo M, Rogatsky I. 2015. Minireview: nuclear receptor coregulators of the p160 family: insights into inflammation and metabolism. Mol. Endocrinol. 29:502-17
84. Marmorstein R, Zhou MM. 2014. Writers and readers of histone acetylation: structure, mechanism, and inhibition. Cold Spring Harb. Perspect. Biol. 6:a018762
85. Duan K, Gomez Hernandez K, Mete O. 2015. Clinicopathological correlates of adrenal Cushing's syndrome. J. Clin. Pathol. 68:175-86
86. Raff H, Carroll T. 2015. Cushing's syndrome: from physiological principles to diagnosis and clinical care. J. Physiol. 593:493-506
87. van RaalteDH, Brands M, van der Zijl NJ,Muskiet MH, Pouwels PJW, et al. 2011. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 54:2103-12
88. Kauh E, Mixson L, Malice MP, Mesens S, Ramael S, et al. 2011. Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals. Eur. J. Endocrinol. 166:459-67
89. Burt MG, Willenberg VM, Petersons CJ, Smith MD, Ahern MJ, Stranks SN. 2012. Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology 51:1112-19
90. Asrih M, Jornayvaz FR. 2015. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol. Cell. Endocrinol. 418:55-65
91. Kowalski GM, Bruce CR. 2014. The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. Am. J. Physiol. Endocrinol. Metab. 307:E859-71
92. Rafacho A, Ortsater H, Nadal A, Quesada I. 2014. Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. J. Endocrinol. 223:R49-62
93. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, et al. 1995. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev. 9:1608-21
94. Jitrapakdee S. 2012. Transcription factors and coactivators controlling nutrient and hormonal regulation of hepatic gluconeogenesis. Int. J. Biochem. Cell Biol. 44:33-45
95. Opherk C, Tronche F, Kellendonk C, Kohlmüller D, Schulze A, et al. 2004. Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. Mol. Endocrinol. 18:1346-53
96. Rose AJ, Herzig S. 2013. Metabolic control through glucocorticoid hormones: an update. Mol. Cell. Endocrinol. 380:65-78
97. Liang Y, Osborne MC,Monia BP, Bhanot S,Watts LM, et al. 2005. Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice. Metabolism 54:848-55
98. Jacobson PB. 2005. Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. J. Pharmacol. Exp. Ther. 314:191-200
99. Yang J, Reshef L, Cassuto H, Aleman G, Hanson RW. 2009. Aspects of the control of phosphoenolpyruvate carboxykinase gene transcription. J. Biol. Chem. 284:27031-35
100. Bernal-Mizrachi C,Weng S, Feng C, Finck BN, Knutsen RH, et al. 2003. Dexamethasone induction of hypertension and diabetes is PPAR-αdependent in LDL receptor-null mice. Nat. Med. 9:1069-75
101. Boergesen M, Pedersen TA, Gross B, van Heeringen SJ, Hagenbeek D, et al. 2012. Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor α in mouse liver reveals extensive sharing of binding sites. Mol. Cell. Biol. 32:852-67
102. Lee JM, Wagner M, Xiao R, Kim KH, FengD, et al. 2014. Nutrient-sensing nuclear receptors coordinate autophagy. Nature 516:112-15
103. Patel R, Patel M, Tsai R, Lin V, Bookout AL, et al. 2011. LXR βis required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J. Clin. Investig. 121:431-41
104. Renga B,Mencarelli A, D'Amore C, Cipriani S, Baldelli F, et al. 2012. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB J. 26:3021-31
105. Liu S, Croniger C, Arizmendi C, Harada-Shiba M, Ren J, et al. 1999. Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBP βgene. J. Clin. Investig. 103:207-13
106. ArnaldiG, ScandaliVM,TrementinoL, CardinalettiM,Appolloni G, BoscaroM. 2010. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology 92:86-90
107. Rockall A, Sohaib S, Evans D, Kaltsas G, Isidori A, et al. 2003. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur. J. Endocrinol. 149:543-48
108. Lemke U, Krones-Herzig A, Diaz MB, Narvekar P, Ziegler A, et al. 2008. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab. 8:212-23
109. Revollo JR, Oakley RH, Lu NZ, Kadmiel M, Gandhavadi M, Cidlowski JA. 2013. HES1 is a master regulator of glucocorticoid receptor-dependent gene expression. Sci. Signal. 6:ra103
110. Peckett AJ, Wright DC, Riddell MC. 2011. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism 60:1500-10
111. Fain JN, Kovacev VP, Scow RO. 1965. Effect of growth hormone and dexamethasone on lipolysis and metabolism in isolated fat cells of the rat. J. Biol. Chem. 240:3522-29
112. Samra JS, ClarkML, Humphreys SM,MacDonald IA, Bannister PA, Frayn KN. 1998. Effects of physiological hypercortisolemia on the regulation of lipolysis in subcutaneous adipose tissue. J. Clin. Endocrinol. Metab. 83:626-31
113. Lee MJ, Pramyothin P, Karastergiou K, Fried SK. 2014. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim. Biophys. Acta 1842:473-81
114. Rebuffe-ScriveM,Krotkiewski M, Elfverson J, Bjorntorp P. 1988. Muscle and adipose tissuemorphology and metabolism in Cushing's syndrome. J. Clin. Endocrinol. Metab. 67:1122-28
115. Yu CY, Mayba O, Lee JV, Tran J, Harris C, et al. 2010. Genome-wide analysis of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in triglyceride homeostasis. PLOS ONE 5:e15188
116. Asada M, Rauch A, Shimizu H, Maruyama H, Miyaki S, et al. 2010. DNA binding-dependent glucocorticoid receptor activity promotes adipogenesis via Kr üppel-like factor 15 gene expression. Lab. Investig. 91:203-15
117. Laudet V, Lahnalampi M, Heinäniemi M, Sinkkonen L,WabitschM, Carlberg C. 2010. Time-resolved expression profiling of the nuclear receptor superfamily in human adipogenesis. PLOS ONE 5:e12991
118. Mikkelsen TS, Xu Z, Zhang X, Wang L, Gimble JM, et al. 2010. Comparative epigenomic analysis of murine and human adipogenesis. Cell 143:156-69
119. Siersbaek R, Nielsen R, John S, Sung MH, Baek S, et al. 2011. Extensive chromatin remodelling and establishment of transcription factor 'hotspots' during early adipogenesis. EMBO J. 30:1459-72
120. Kang S, Tsai LT, Zhou Y, Evertts A, Xu S, et al. 2015. Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis. Nat. Cell Biol. 17:44-56
121. Kuo T, Harris CA, Wang J-C. 2013. Metabolic functions of glucocorticoid receptor in skeletal muscle. Mol. Cell. Endocrinol. 380:79-88
122. Lofberg E, Gutierrez A, Wernerman J, Anderstam B, Mitch WE, et al. 2002. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur. J. Clin. Investig. 32:345-53
123. Braun TP, Zhu X, Szumowski M, Scott GD, Grossberg AJ, et al. 2011. Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J. Exp. Med. 208:2449-63
124. Short KR, Bigelow ML, Nair KS. 2009. Short-term prednisone use antagonizes insulin's anabolic effect on muscle protein and glucose metabolism in young healthy people. Am. J. Physiol. Endocrinol. Metab. 297:E1260-68
125. Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149:274-93
126. Schiaffino S, Mammucari C. 2011. Regulation of skeletalmuscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet. Muscle 1:4
127. Yamazaki Y, Kamei Y, Sugita S, Akaike F, Kanai S, et al. 2010. The cathepsin L gene is a direct target of FOXO1 in skeletal muscle. Biochem. J. 427:171-78
128. Schakman O, Kalista S, Barbe C, Loumaye A, Thissen JP. 2013. Glucocorticoid-induced skeletal muscle atrophy. Int. J. Biochem. Cell Biol. 45:2163-72
129. Kuo T, Lew MJ, Mayba O, Harris CA, Speed TP,Wang JC. 2012. Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. PNAS 109:11160-65
130. Watson ML, Baehr LM, Reichardt HM, Tuckermann JP, Bodine SC, Furlow JD. 2012. A cellautonomous role for the glucocorticoid receptor in skeletal muscle atrophy induced by systemic glucocorticoid exposure. Am. J. Physiol. Endocrinol. Metab. 302:E1210-20
131. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, et al. 2008. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am. J. Physiol. Endocrinol. Metab. 295:E785-97
132. Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, et al. 2011. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. 13:170-82
133. Lutzner N, Kalbacher H, Krones-Herzig A, Rosl F. 2012. FOXO3 is a glucocorticoid receptor target and regulates LKB1 and its own expression based on cellular AMP levels via a positive autoregulatory loop. PLOS ONE 7:e42166
134. Wang H, Kubica N, Ellisen LW, Jefferson LS, Kimball SR. 2006. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J. Biol. Chem. 281:39128-34
135. Britto FA, Begue G, Rossano B, Docquier A, Vernus B, et al. 2014. REDD1 deletion prevents dexamethasone-induced skeletal muscle atrophy. Am. J. Physiol. Endocrinol. Metab. 307:E983-93
136. Kagan JC, BartonGM. 2015. Emerging principles governing signal transduction by pattern-recognition receptors. Cold Spring Harb. Perspect. Biol. 7:a016253
137. Matzinger P. 2002. The danger model: a renewed sense of self. Science 296:301-5
138. BesedovskyH, Sorkin E, KellerM,Muller J. 1975. Changes in blood hormone levels during the immune response. Proc. Soc. Exp. Biol. Med. 150:466-70
139. Bhattacharyya S, Brown DE, Brewer JA, Vogt SK,Muglia LJ. 2007. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 109:4313-19
140. Goodwin JE, Feng Y, Velazquez H, Sessa WC. 2013. Endothelial glucocorticoid receptor is required for protection against sepsis. PNAS 110:306-11
141. Sevilla LM, Latorre V, Sanchis A, Perez P. 2013. Epidermal inactivation of the glucocorticoid receptor triggers skin barrier defects and cutaneous inflammation. J. Investig. Dermatol. 133:361-70
142. Oakley RH, Ren R, Cruz-Topete D, Bird GS, Myers PH, et al. 2013. Essential role of stress hormone signaling in cardiomyocytes for the prevention of heart disease. PNAS 110:17035-40
143. Oppong E, Flink N, Cato AC. 2013. Molecular mechanisms of glucocorticoid action in mast cells. Mol. Cell. Endocrinol. 380:119-26
144. ZenM, CanovaM, Campana C, Bettio S,Nalotto L, et al. 2011. The kaleidoscope of glucorticoid effects on immune system. Autoimmun. Rev. 10:305-10
145. Vandevyver S, Dejager L, Van Bogaert T, Kleyman A, Liu Y, et al. 2012. Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation. J. Clin. Investig. 122:2130-40
146. Bereshchenko O, Coppo M, Bruscoli S, Biagioli M, Cimino M, et al. 2014. GILZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-β signaling. Cell Rep. 7:464-75
147. AltonsyMO, Sasse SK, Phang TL, Gerber AN. 2014. Context-dependent cooperation between nuclear factor κB (NF-κB) and the glucocorticoid receptor at a TNFAIP3 intronic enhancer: a mechanism to maintain negative feedback control of inflammation. J. Biol. Chem. 289:8231-39
148. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. 1995. Role of transcriptional activation of IκBαin mediation of immunosuppression by glucocorticoids. Science 270:283-86
149. Yang YH, Aeberli D, Dacumos A, Xue JR, Morand EF. 2009. Annexin-1 regulates macrophage IL-6 and TNF via glucocorticoid-induced leucine zipper. J. Immunol. 183:1435-45
150. Chinenov Y, Coppo M, Gupte R, Sacta MA, Rogatsky I. 2014. Glucocorticoid receptor coordinates transcription factor-dominated regulatory network in macrophages. BMC Genomics 15:656
151. Vandevyver S, Dejager L, Tuckermann J, Libert C. 2013. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology 154:993-1007
152. Abraham SM, Lawrence T, Kleiman A, Warden P, MedghalchiM, et al. 2006. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J. Exp. Med. 203:1883-89
153. Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, et al. 2006. Dynamic regulation of pro-and antiinflammatory cytokines byMAPKphosphatase 1 (MKP-1) in innate immune responses.PNAS103 2274-79
154. Maier JV, Brema S, Tuckermann J, Herzer U, Klein M, et al. 2007. Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol. Endocrinol. 21:2663-71
155. Beaulieu E,Morand EF. 2011. Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. Nat. Rev. Rheumatol. 7:340-48
156. De Bosscher K, Beck IM, Dejager L, Bougarne N, Gaigneaux A, et al. 2014. Selective modulation of the glucocorticoid receptor can distinguish between transrepression of NF-κB and AP-1. Cell. Mol. Life Sci. 71:143-63
157. Rogatsky I, Zarember KA, Yamamoto KR. 2001. Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J. 20:6071-83
158. Chinenov Y, Gupte R, Dobrovolna J, Flammer JR, Liu B, et al. 2012. Role of transcriptional coregulator GRIP1 in the anti-inflammatory actions of glucocorticoids. PNAS 109:11776-81
159. Gilchrist DA, Fromm G, dos Santos G, Pham LN,McDaniel IE, et al. 2012. Regulating the regulators: the pervasive effects of Pol II pausing on stimulus-responsive gene networks. Genes Dev. 26:933-44
160. Adelman K, Kennedy MA, Nechaev S, Gilchrist DA, Muse GW, et al. 2009. Immediate mediators of the inflammatory response are poised for gene activation through RNA polymerase II stalling. PNAS 106:18207-12
161. Diefenbacher M, Sekula S, HeilbockC,Maier JV, LitfinM, et al. 2008. Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1. Mol. Endocrinol. 22:1767-80
162. Diefenbacher ME, Reich D, Dahley O, Kemler D, Litfin M, et al. 2014. The LIM domain protein nTRIP6 recruits the mediator complex to AP-1-regulated promoters. PLOS ONE 9:e97549
163. Chen SH, Masuno K, Cooper SB, Yamamoto KR. 2013. Incoherent feed-forward regulatory logic underpinning glucocorticoid receptor action. PNAS 110:1964-69